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Mycoplasma hyopneumoniae is the causative agent of porcine enzootic pneumonia, a chronic and economically
significant respiratory disease that affects swine production worldwide. M. hyopneumoniae adheres to and
adversely affects the function of ciliated epithelial cells of the respiratory tract, and the cilium adhesin
(Mhp183, P97) is intricately but not exclusively involved in this process. Although binding of pathogenic
bacteria to glycosaminoglycans is a recognized step in pathogenesis, knowledge of glycosaminoglycan-binding
proteins in M. hyopneumoniae is lacking. However, heparin and other sulfated polysaccharides are known to
block the binding ofM. hyopneumoniae to purified swine respiratory cilia. In this study, four regions within the
cilium adhesin were examined for the ability to bind heparin. Cilium adhesin fragments comprising 653 amino
acids of the N terminus and 301 amino acids of the C terminus (containing two repeat regions, R1 and R2) were
cloned and expressed. These fragments bound heparin in a dose-dependent and saturable manner with
physiologically significant binding affinities of 0.27  0.02 M and 1.89  0.33 M, respectively. Heparin
binding of both fragments was strongly inhibited by the sulfated polysaccharides fucoidan and mucin but not
by chondroitin sulfate B. When the C-terminal repeat regions R1 and R2 were cloned separately and expressed,
heparin-binding activity was lost, suggesting that both regions are required for heparin binding. The ability of
the cilium adhesin to bind heparin indicates that this molecule plays a multifunctional role in the adherence
of M. hyopneumoniae to host respiratory surfaces and therefore has important implications with respect to the
pathogenesis of this organism.
Mycoplasma hyopneumoniae is the etiological agent of por-
cine enzootic pneumonia, a chronic respiratory disease that
causes significant economic losses to the swine industry (30).
Infections are established via colonization of porcine respira-
tory epithelia, a process initiated by the adherence of bacterial
cells to host cilia. Successful colonization results in ciliostasis
and shedding of cilia from the epithelial surface, thereby dis-
rupting the mucociliary escalator and leaving the host suscep-
tible to secondary infections (3, 9).
Studies have shown that the cilium adhesin P97 is essential
for the adherence of M. hyopneumoniae and the onset of dis-
ease (15, 37). The cilium adhesin gene (mhp183) encodes a
126-kDa preprotein. The full-length protein is barely present
in in vitro-grown cells due to posttranslational processing. A
major cleavage event at position 195 generates the functional
adhesin (P97) and the N-terminal fragment (P22). P97 is fur-
ther cleaved to yield a host of other peptides (10). While the
functions of these peptides (apart from P97) are unknown,
proteomic and immunogold studies demonstrate that they re-
main associated with the cell surface or the surrounding matrix
(10).
Like several other characterized mycoplasma adhesins, P97
contains repetitive elements within the C-terminal portion of
its amino acid sequence (4, 8, 15). P97 contains two such repeat
regions, designated R1 and R2, with R1 (sequence AAKPV/E)
being identified as the cilium-binding epitope (16). Size varia-
tion in the cilium adhesin protein of different M. hyopneu-
moniae strains (95 to 97 kDa) has been accounted for by
differences in the number of copies of R1, which varies from 9
in the nonadherent J strain to 15 in the pathogenic 232 strain
(35). A minimum of eight copies of the R1 repeat is necessary
for cilium binding, but this is not sufficient to confer the ability
to adhere in vivo (16, 23). These data suggest that there are
additional proteins and mechanisms involved in adherence to
host epithelia.
The importance of binding to host extracellular matrix
(ECM) components in initiating pathogenic processes has
been well documented. By binding to ECM proteins such as
fibronectin, vitronectin, laminin, and collagen, pathogenic mi-
crobes are able to mediate interactions with host cells (27) and,
in some cases, enhance their invasive potential (12, 18, 28).
Furthermore, it has been demonstrated that many pathogens
are able to recruit exogenous glycosaminoglycans (e.g., hepa-
rin, heparan sulfate, and chondroitin sulfate B) to their sur-
faces to facilitate interactions between the pathogen and host
ECM components, which are themselves glycosaminoglycan-
binding proteins (13, 21, 34). Binding to glycosaminoglycans is
also believed to enable pathogenic bacteria to evade the host
immune system (7, 12) and modulate the inflammatory re-
sponse (13) by allowing bridging interactions with host chemo-
kines and cytokines. Thus, glycosaminoglycan-binding proteins
are considered to be of central importance to the infection
process.
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Previous experiments have revealed that adherence of puri-
fied recombinant P97 to cilia is inhibited by sulfated glycos-
aminoglycans (15). These findings suggest a possible interac-
tion between the P97 protein and sulfated glycosaminoglycans,
which may act as receptor analogs for the M. hyopneumoniae
adhesin (15, 36, 38); however; these studies did not directly
demonstrate such an interaction. Furthermore, the domains
within the cilium adhesin responsible for this interaction were
not identified. In this study, we identify regions within the
cilium adhesin that interact with the glycosaminoglycan hepa-
rin. The ability of M. hyopneumoniae cell surface molecules to
bind heparin may play a significant role in the pathogenesis of
this organism.
MATERIALS AND METHODS
Bacterial strains and plasmids.M. hyopneumoniae strain J (NCTC 10110) was
cultivated to mid-log phase (medium pH range, 6.8 to 7.2) in modified Friis broth
at 37°C on a rotary shaker as described previously (33). The Escherichia coli
plasmid expression and maintenance strains were M15(pREP4) and JM109,
respectively, and they were grown in Luria-Bertani medium (31) at 37°C. Broth
cultures were incubated on a rotary shaker at 200 to 250 rpm to achieve aeration.
For selection of transformants, Luria-Bertani medium was supplemented with
100 g/ml ampicillin and 50 g/ml kanamycin as required.
DNA extraction. Chromosomal DNA was extracted from the J strain of M.
hyopneumoniae by a phenol-chloroform method, followed by dialysis against TE
buffer as described previously (11). Plasmid DNA was extracted from E. coli with
either the QIAGEN mini-prep or midi-prep kit according to the manufacturer’s
instructions (QIAGEN, Alameda, Calif.).
Plasmid constructs. Adhesin molecules from two different strains of M. hyo-
pneumoniae were used to generate polyhistidine fusion proteins of different
regions of the coding sequence. Because UGA codons encode tryptophan in
mycoplasmas, they cause translation problems in E. coli, resulting in premature
stops during the expression of cloned sequences. To circumvent this problem,
three clones were generated by amplifying chromosomal DNA from strain J with
PCR primers designed to avoid in-frame TGA codons. An additional construct
was generated with a clone containing a large fragment of the P97 sequence from
strain P5722 (19) in which the TGA codons had been mutagenized to TGGs.
This approach was deemed valid because the sequence difference between these
two P97 homologs is less than 4%, with most of the difference accounted for by
variation in the number of R1 and R2 repeats.
The first construct contained the region coding for the N terminus of the
cilium adhesin (amino acids 106 to 758 of the mutagenized gene sequence) and
was referred to as F1P97. The PCR template for this construct was pISM405, in
which the TGA codons had been converted to TGGs (10). The second construct,
referred to as F2P97 (amino acids 768 to 1069 of the J strain sequence), contained
the cilium adhesin repeat domains coding for both R1, the cilium-binding
epitope, and R2. This gene fragment was further subcloned to yield two addi-
tional constructs referred to as F3P97 (amino acids 768 to 914 of the J strain
sequence) and F4P97 (amino acids 935 to 1069 of the J strain sequence), which
contained the R1 and R2 regions, respectively (Fig. 1).
To clone specific sequences, gene fragments were amplified via PCR with Taq
polymerase (QIAGEN). The primers used for amplification of the gene frag-
ments encoding F1P97, F3P97, and F4P97 were F1F (5-GGGGATCCCAAGAT
CCTGAATATACC) and F1R (5-GGCTGCAGTTAGGCTGCTTTAAGGAA
AAATGC) (underlined sequences represent BamHI and PstI restriction sites,
respectively), F3F (5-GGGTCGACAAATTAGACGATAATCTTCAG) and
F3R (5-GGCTGCAGTTACTCGCTTTGATGAACTAGTTC) (underlined se-
quences represent SalI and PstI restriction sites, respectively), and F4F (5-
GGGGATCCCAGGAAGTCAAGGTAACTAGT) and F4R (5-GGCTGCAG
CCCGGGTTAGGATCACCGGATTTTGAATC) (underlined sequences rep-
resent BamHI and PstI restriction sites, respectively). Primers F3F and F4R were
used to amplify the gene fragment corresponding to F2P97. Cilium adhesin
fragments F1P97 to F4P97 were digested with the appropriate restriction enzymes
and ligated into linearized pQE-9 with 1 U of T4 DNA ligase (Roche, Basel,
Switzerland) at 10°C overnight. Ligated plasmids were electroporated into E. coli
M15(pREP4) cells with a Bio-Rad Gene Pulser (Bio-Rad Laboratories, Her-
cules, Calif.) at 2.5 kV, 25 F, and 200  according to the manufacturer’s
instructions. All plasmid constructs were confirmed via DNA sequencing.
Protein expression and purification. All cilium adhesin fragments were ex-
pressed as hexahistidyl fusion proteins and purified by nickel affinity chromatog-
raphy. Briefly, E. coli M15(pREP4) cells were grown to mid-log phase and
induced with a final concentration of isopropyl--D-thiogalactopyranoside of 1
mM. Cells were harvested by centrifugation (4,000 g for 20 min) and then lysed
in 8 M urea buffer (8 M urea, 0.01 M Tris, 0.1 M NaH2PO4, pH 8.0) with gentle
rocking for 1 h. Cell debris was pelleted by centrifugation at 10,000  g for 30
min. To the supernatant, 0.25 volume of a 50% Ni-nitrilotriacetic acid slurry
(QIAGEN) was added and the solution was allowed to mix gently for 1 h. The
solution was loaded onto a glass column and washed twice with 8 M urea buffer
(pH 6.3) to remove unbound protein. Bound protein was eluted with low-pH
urea buffers (pH 5.9 and pH 4.5). Proteins were analyzed for purity by sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and then dialyzed for
48 h with multiple buffer changes against phosphate-buffered saline (PBS; 10
mM sodium phosphate, 150 mM sodium chloride, pH 7.4)–0.1% SDS or
PBS–5% glycerol to remove the urea. The concentration of the purified proteins
was estimated by the Bradford assay (Bio-Rad Laboratories).
Production of polyclonal antisera. Antisera to the F1P97 to F4P97 adhesin
fragments were generated via primary and secondary intramuscular injections of
antigen into New Zealand White rabbits at 2-week intervals. Antigens (approx-
imately 0.5 mg) were prepared for injection by mixing equal volumes of purified
protein (approximately 500 l) and Freund’s incomplete adjuvant (Sigma Al-
drich, St. Louis, Missouri). Preimmune serum was collected prior to the primary
injection and served as control antiserum. A trial bleeding was performed 10 to
14 days after the secondary injection of antigen, and immune responses to the
antigen at this stage were assessed via immunoblotting. Positive sera were col-
lected via cardiac bleeding, during which the rabbits were anesthetized and
euthanized as previously described (32).
Heparin-binding assays. For ligand dot blot assays, purified proteins were
diluted to 5 g/ml in PBS. To denature samples, proteins were diluted in cracking
buffer (60 mM Tris, pH 6.8, 1% SDS, 1% -mercaptoethanol, 10% glycerol) and
boiled for 5 min. A 100-l volume of each sample was spotted onto a Hybond-C
super nitrocellulose membrane (Amersham Pharmacia Biotech, Uppsala, Swe-
den) that had been prewetted in Tris-buffered saline (TBS; 10 mM Tris, 150 mM
sodium chloride, pH 7.4) with a Bio-Dot microfiltration apparatus (Bio-Rad
Laboratories). The membrane was blocked with 300 l per well of blocking
solution (1% bovine serum albumin [BSA] in TBS) and then washed twice under
vacuum with 300 l per well of TTBS wash solution (0.05% Tween 20 in TBS).
The membrane was removed from the manifold and placed in a dish containing
100 g/ml biotinylated heparin (Sigma) diluted in 1% BSA-TTBS. The mem-
brane was incubated for 1 h with gentle rocking and then washed 3  10 min in
TTBS. Streptavidin peroxidase (Roche) was diluted 1:3,000 in 1% BSA-TTBS
and added to the membrane. After 1 h of incubation, the blot was washed 3 
10 min with TTBS. The membrane was equilibrated with 100 mM Tris (pH 7.6)
and developed with 3,3-diaminobenzidine (Sigma) solution. To ensure that
equivalent amounts of protein had been blotted in each position, a duplicate blot
was stained with amido black protein stain (0.1% amido black, 7% [vol/vol] acetic
acid) immediately after spotting of the proteins onto nitrocellulose.
For microtiter plate binding assays, 96-well plates (Linbro/Titertek; ICN Bio-
medicals Inc., Aurora, Ohio) were coated overnight in a humidified chamber
with 0.5 g per well purified protein diluted in 100 l carbonate coating buffer
(18 mM NaHCO3, 27 mM Na2CO3, pH 9.5). Following overnight incubation, the
plates were washed five times with PBS–0.2% Tween 20 (200 l wash solution
per well) with an automatic 96PW plate washer (SLT Labinstruments,
Crailsheim, Germany). The wells were blocked with 100 l of blocking solution
(2% skim milk in PBS) for 1 h in a humidified chamber. The plates were washed
five times, and biotinylated heparin which had been prediluted in 1% skim
milk–PBS was added in increasing concentrations to the wells. Final concentra-
tions of biotinylated heparin were 0, 1, 5, 10, 20, 50, and 100 g/ml. Aliquots of
100 l of each concentration were added to microtiter plate wells; the plates were
then incubated for 1 h. After washing the plates as described above, 100 l of
streptavidin-peroxidase (Roche) diluted 1:3,000 in 1% skim milk–PBS was added
to each well and the mixture was incubated for 1 h. The plates were washed and
developed with 1 mM 2,2-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) sub-
strate (Sigma) in citrate buffer (100 mM citric acid, 200 mM Na2HPO4, pH 4.2)
which had been activated with hydrogen peroxide. Plates were developed with
shaking on a Titramax 1000 microtiter plate shaker (Heidolph, Schwabach,
Germany), and the optical density at 414 nm was measured with a Multiskan
Ascent plate reader (Thermo Labsystems, Franklin, Mass.) at 7-, 15-, 25-, and
45-min intervals.
Microtiter plate assays for determining the specificity of heparin binding were
performed as described above but with serial twofold dilutions of biotinylated
heparin, beginning at a saturating concentration (100 g/ml for F1P97 and 50
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g/ml for F2P97), each of which was premixed with a 50-fold excess of unlabeled
heparin prior to addition to the plates.
Competitive-binding assays were also performed as above but with the addi-
tion of a 1-, 5-, 10-, 20-, 30-, 40-, or 50-fold excess of a range of sulfated
polysaccharides. Inhibitors were premixed with biotinylated heparin immediately
prior to addition to the wells and included unlabeled heparin, fucoidan, mucin,
and chondroitin sulfate B (Sigma). In all microtiter plate assays, controls were
performed with uncoated wells, wells where no heparin was added, or wells
where no streptavidin-peroxidase was added. Controls which employed protein-
specific antiserum and horseradish peroxidase-labeled anti-rabbit immunoglob-
ulin G (Chemicon, Temecula, Calif.) were also conducted to ensure that proteins
were adhering to the microtiter plate wells. All experiments were performed in
triplicate. Results were graphed by GraphPad Prism version 4.02 for Windows
(GraphPad Software, San Diego, Calif.; www.graphpad.com) by nonlinear re-
gression.
RESULTS
Bioinformatic identification of putative heparin-binding
motifs. The cilium adhesin was examined for potential hepa-
rin-binding sites within its amino acid sequence by using es-
tablished criteria (5, 6). In many instances, glycosaminoglycan-
binding proteins are reported to contain consensus sequences
of two types: XBBXBX and XBBBXXBX, where B represents
a basic residue and X is any other amino acid. The F1P97 and
F2P97-F3P97 domains of the cilium adhesin each contain one
motif that matches the former consensus sequence (DKKDKS
and DKKVKE, respectively) (Fig. 2). Several heparin-binding
proteins have been identified that do not contain the consensus
sequences but possess sequences that are relatively rich in
basic residues (20, 29). Both F1P97 and F2P97 also contain
relatively large numbers of basic amino acids across the lengths
of their sequences (Fig. 2).
Heparin-binding assays. To determine whether the cilium
adhesin fragments bound to heparin and to assess the impor-
tance of their protein conformation in this process, ligand blot
assays were performed. Standard ligand blot assays involving
the transfer of proteins from denaturing polyacrylamide gels to
polyvinylidene difluoride gave only weak or unreliable results
(data not shown). In a dot blot assay, strong and reproducible
reactions with biotinylated heparin were observed for undena-
tured F1P97 and F2P97, while a weak reaction was observed for
undenatured F4P97 (Fig. 3). Interestingly, the same protein
fragments did not show a strong reaction with heparin when
they were denatured prior to blotting, indicating that protein
conformation may play a role in the interaction with heparin.
FIG. 1. (A) Diagrammatic representation of the cilium adhesin gene. Arrows indicate the locations of primers used to amplify DNA fragments
coding for F1P97 to F4P97. Amino acid (aa) positions corresponding to the N and C termini of F1P97 to F4P97 are indicated. Numbers marked with
asterisks indicate positions corresponding to the cilium adhesin of M. hyopneumoniae strain P5722 (GenBank accession no. AAB03497); all other
numbers correspond to the cilium adhesin of M. hyopneumoniae strain J (GenBank accession no. AAC35402). The F1P97 to F4P97 adhesin fragment
sizes are indicated. (B) SDS-polyacrylamide gel showing the purified, recombinant F1P97 to F4P97 cilium adhesin fragments. Lane 1, prestained
protein molecular weight marker (MBI Fermentas, Hanover, Maryland; band sizes correspond to 118, 86, 47, 34, 26, and 19 kDa); lane 2, F1P97;
lane 3, F2P97; lane 4, F3P97; lane 5, F4P97. All cilium adhesin fragments run at higher molecular weights than predicted due to abnormal migration
patterns.
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Quantification of heparin binding by the cilium adhesin do-
mains and determination of binding affinities was performed
by a microtiter plate binding assay. Recombinant cilium adhe-
sin fragments F1P97 to F4P97 were shown to reliably bind to
microtiter plates by interacting with fragment-specific antibod-
ies (data not shown). Experiments were then performed with
increasing amounts of biotinylated heparin up to a saturating
concentration. Figure 4 indicates the total binding (specific and
nonspecific) of the cilium adhesin fragments to heparin. Both
F1P97 and F2P97 were found to bind heparin in a dose-depen-
dent and saturable manner. In contrast, F3P97 and F4P97
showed low-level, nonsaturable binding, indicating a nonspe-
cific interaction. Interestingly, despite being subfragments of
F2P97, F3P97 and F4P97 continued to show low-level binding
when pooled and assayed for heparin-binding activity (data not
shown). This result supports the ligand dot blot data, which
suggest that the conformation of F2P97 is essential for heparin
binding.
To determine whether the binding of F1P97 and F2P97 to
heparin was the result of a specific interaction, binding assays
FIG. 2. Amino acid sequences of F1P97 to F4P97. The sequences shown correspond to the M. hyopneumoniae strains and numbering described
in Fig. 1A. F3P97 and F4P97 are indicated by large boxes. Small boxes indicate motifs matching the heparin-binding consensus sequences. Basic
residues are shaded. Tryptophan residues that represent mutagenized TGG codons are underlined. Repeat regions 1 and 2 (R1 and R2) are
italicized and underscored.
FIG. 3. Dot blot assay of denatured and undenatured cilium adhe-
sin fragments reacted with biotinylated heparin (A) and stained with
amido black (B). Position 1, undenatured F1P97; position 2, denatured
F1P97; position 3, undenatured F2P97; position 4, denatured F2P97;
position 5, undenatured F3P97; position 6, denatured F3P97; position 7,
undenatured F4P97; position 8, denatured F4P97.
FIG. 4. Binding of biotinylated heparin to immobilized cilium ad-
hesin domains F1P97 (F), F2P97 (E), F3P97 (■), and F4P97 (). Increas-
ing concentrations of biotinylated heparin were added until saturation
was reached. Absorbances were read after 45 min of incubation in the
presence of substrate. Error bars indicate the standard deviation from
the mean for triplicate readings. Replicate experiments resulted in
similar binding curves.
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were undertaken in which biotinylated heparin was added in
the presence or absence of a 50-fold concentration of unla-
beled heparin. Binding of heparin to both F1P97 and F2P97 was
shown to be highly specific with minimal nonspecific binding
observed (Fig. 5A and B). Affinity constants were determined
by using the specific binding data (total binding minus nonspe-
cific binding) and were found to be 0.27  0.02 M and 1.89 
0.33 M for F1P97 and F2P97, respectively. These values are
comparable to those derived from replicate experiments.
Inhibition of heparin binding by sulfated polysaccharides.
The nature of the interaction between the cilium adhesin frag-
ments and heparin was further characterized in competitive-
binding experiments with the sulfated polysaccharides heparin,
fucoidan, mucin, and chondroitin sulfate B. For both F1P97 and
F2P97, biotinylated heparin binding was significantly inhibited
by heparin. Furthermore, for both F1P97 and F2P97, fucoidan
and mucin were shown to be strong competitors while chon-
droitin sulfate B did not inhibit the interaction of heparin with
either adhesin domain (Fig. 6A and B). Notably, both fucoidan
and mucin gave stronger inhibition than unlabeled heparin.
These results suggest that both F1P97 and F2P97 are able to
bind fucoidan and mucin in addition to heparin.
DISCUSSION
In order to establish infection, bacterial pathogens must first
adhere to and colonize host epithelia. For many bacteria, the
initial site of contact with host tissues is at the level of the
ECM; therefore, the ability to bind components of the ECM is
widespread among pathogenic microbes (12, 13, 22, 34). Be-
cause of their fastidious nature and obligate parasitic mode of
life, mycoplasmas require particularly efficient mechanisms for
adherence. For M. hyopneumoniae, knowledge about the
mechanisms of adhesion to host tissues is currently confined to
the cilium adhesin and its interaction with the cilia of the
porcine respiratory tract (15, 17, 23, 37). No ECM-binding
proteins have been identified in this organism; however, pre-
vious studies indicated that binding of the cilium adhesin to
cilia could be inhibited by heparin, providing indirect evidence
that the adhesin is able to bind this molecule (15, 38).
In this study, two nonoverlapping regions of the M. hyopneu-
moniae cilium adhesin, F1P97 and F2P97, were shown to bind
heparin in a dose-dependent, saturable manner. These results
indicate that there are at least two distinct heparin-binding
domains within the adhesin protein. Both of these regions
contain clusters of basic amino acids that match the consensus
FIG. 5. Heparin-binding curves for F1P97 (A) and F2P97 (B) show-
ing total binding (F), nonspecific binding (■), and specific binding (E).
Total binding was determined by the standard microtiter plate assay
protocol, while nonspecific binding was determined in the presence of
a 50-fold excess of unlabeled heparin. The specific binding curves were
derived by subtracting the nonspecific binding data from the total
binding data. Error bars indicate the standard deviation from the mean
for triplicate readings.
FIG. 6. Competitive-binding assays showing inhibition of heparin
binding to F1P97 (A) and F2P97 (B) by various sulfated polysaccharides,
i.e., unlabeled heparin (F), fucoidan (■), mucin (E), and chondroitin
sulfate B (). Microtiter plate binding assays were performed by the
standard protocol but with an excess of each inhibitor. Error bars
indicate the standard deviation from the mean for triplicate readings.
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for glycosaminoglycan-binding motifs (6). One of these protein
regions, F2P97, contains both of the cilium adhesin repeat re-
gions, R1 and R2. The heparin-binding consensus motif of
F2P97 lies within the F3P97 region (Fig. 1A), which suggests
that F3P97 should also bind heparin. As F3P97 was not shown to
bind heparin in either the ligand blot or the microtiter plate
assay, it must be concluded that the heparin-binding motif in
F2P97 alone was not sufficient to confer binding activity, indi-
cating that additional sequences are required. F4P97 also failed
to show any significant interaction with heparin in microtiter
plate assays, indicating that while R1 and R2 are unable to
bind heparin independently, the intact F2P97 fragment (con-
taining both of these regions) displays heparin-binding activity.
The fact that both of the cilium adhesin repeat regions are
required for heparin binding suggests that this interaction is
conformation dependent rather than due to the presence of a
specific linear amino acid motif. Furthermore, the idea that
protein conformation plays a role in heparin binding is sup-
ported by the ligand blot assay data, which demonstrated that
undenatured F1P97 and F2P97 were able to bind heparin while
the denatured forms were unable to do so.
Alternatively, since 20 amino acids (914 to 935) were omit-
ted during the construction of F3P97 and F4P97, it is possible
that this sequence may be responsible for the heparin-binding
activity observed for F2P97. However, an analysis of this se-
quence failed to identify a heparin-binding motif or a basic
amino acid density that might facilitate binding.
Homologues of the cilium adhesin Mhp183 among different
M. hyopneumoniae strains are highly conserved, with the ma-
jority of sequence changes resulting from variations in the
number of repeats within the R1 and R2 regions. Because
these repeat regions are contained within the heparin-binding
F2P97 fragment, the cilium adhesins from different strains of M.
hyopneumoniae might be expected to bind heparin with various
affinities. The M. hyopneumoniae J strain used in this study has
a cilium adhesin with only nine copies of the R1 repeat, while
pathogenic strains have been shown to contain up to 15 copies.
An increase in the number of copies of R1 may therefore
confer an even greater affinity for heparin since this repeat is
rich in basic residues. Further experiments are required to
confirm this.
Studies on the proteolytic cleavage of Mhp183 have revealed
a complex processing pattern. One major processing event
cleaves an N-terminal 22-kDa fragment (P22), generating the
“mature” P97 adhesin (10, 37). A second major event (at
position 862 for the J strain) removes a C-terminal 28-kDa
fragment (P28) that separates the cilium-binding epitope, R1,
from R2. This event generates a central adhesin fragment that
contains R1 and is approximately 66 kDa in size (P66) (10).
Since both R1 and R2 are necessary for the F2P97 fragment of
the adhesin to bind heparin, the cleavage event that generates
P28 is likely to have an impact on the ability of some cilium
adhesin cleavage products to bind glycosaminoglycans. How-
ever, this cleavage event may not have a detrimental effect on
the ability of P66 to bind heparin since this is likely to be
conferred by the second heparin-binding site found in F1P97.
The presence of two distally located heparin-binding sites may
allow M. hyopneumoniae to alter its surface architecture with-
out a corresponding loss of heparin-binding activity.
For some proteins, the ability to bind heparin has been
attributed to the presence of relatively high numbers of evenly
spaced basic amino acid residues rather than the presence of
specific linear motifs (20, 29). The positively charged basic
residues are believed to interact with the exposed, negatively
charged sulfate groups of heparin and other glycosaminogly-
cans (5, 6, 20). This may also be true of cilium adhesin regions
F1P97 and F2P97, which are relatively rich in lysine residues.
Further evidence for this type of interaction can be derived
from competitive-binding assays. Binding of both F1P97 and
F2P97 to heparin was disrupted by the addition of fucoidan, a
highly sulfated fucose polymer derived from marine algae, but
not by chondroitin sulfate B. While not present in mammalian
systems, fucoidan is useful in binding studies due to the high
degree of sulfation of its carbohydrate chains and for this
reason is frequently found to be a potent inhibitor of protein-
heparin interactions (14, 24). The strong inhibition of heparin
binding by fucoidan highlights the significance of sulfate
groups in this interaction.
Mucin, another highly sulfated compound, was also found to
be a powerful inhibitor in our competitive-binding assays. Mu-
cins are abundant in the mucosal secretions lining various
epithelial surfaces (25). Thus, the ability of the cilium adhesin
fragments to bind mucin may in itself be highly significant,
since the mucosal layer is often considered the first defense
against pathogens that colonize epithelial surfaces (1). Inter-
actions with the mucous layer of the respiratory tract would
likely precede binding of M. hyopneumoniae to cilia; therefore,
binding to mucins may represent an important first step in the
pathogenesis of this organism. Further studies are required to
characterize this interaction.
The binding affinities of both F1P97 (0.27  0.02 M) and
F2P97 (1.89  0.33 M) for heparin are within the range
reported for other heparin-binding proteins (0.3 nM to 4 M)
such as antithrombin (2), interleukin-2 and -12 (14, 24), clus-
terin (26), and the mycobacterial heparin-binding hemaggluti-
nin (29), suggesting that these interactions are of physiological
significance. The ability of the M. hyopneumoniae cilium adhe-
sin to bind to components of the ECM, as well as to cilia,
indicates that this molecule plays a multifunctional role in
adherence to the porcine respiratory tract. While more exper-
iments are required to establish the precise role of the adhe-
sin’s interaction with glycosaminoglycans in vivo, studies of
microbial pathogenesis continue to highlight the importance of
binding to heparin and other sulfated polysaccharides in the
establishment, maintenance, and dissemination of infection
(13, 21, 27, 34). Many pathogens, including Neisseria, Yersinia,
and Staphylococcus species, exploit the widespread ability of
host proteins to bind heparin. By recruiting heparin to their
surfaces, these organisms acquire the ability to interact with a
multitude of host molecules and circumvent the need for in-
dividual ligand receptors (13). For organisms such as M. hyo-
pneumoniae, which have small genomes and therefore a lim-
ited repertoire of proteins, the ability to bind exogenous
heparin may significantly increase the potential for host-para-
site interactions at the site of colonization. Host molecules
known to interact with heparin include ECM components,
such as fibronectin and vitronectin, and cytokines and inflam-
matory mediators (13). Thus, the ability of M. hyopneumoniae
to bind heparin may have important implications with respect
to modulation of the host immune system and inflammatory
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response in addition to adherence of the pathogen to host
tissues.
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